Q2 2023 EPS Estimates for Henry Schein, Inc. (NASDAQ:HSIC) Decreased by Analyst

Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) – Research analysts at Zacks Research dropped their Q2 2023 earnings per share (EPS) estimates for Henry Schein in a research report issued on Tuesday, May 23rd. Zacks Research analyst U. Biswas now expects that the company will post earnings per share of $1.24 for the quarter, down from their prior forecast of $1.30. The consensus estimate for Henry Schein’s current full-year earnings is $5.26 per share. Zacks Research also issued estimates for Henry Schein’s Q3 2023 earnings at $1.33 EPS, Q4 2023 earnings at $1.44 EPS, FY2023 earnings at $5.21 EPS, Q1 2024 earnings at $1.35 EPS, Q2 2024 earnings at $1.43 EPS, Q3 2024 earnings at $1.44 EPS, Q4 2024 earnings at $1.41 EPS, FY2024 earnings at $5.63 EPS, Q1 2025 earnings at $1.53 EPS and FY2025 earnings at $6.19 EPS.

A number of other research firms also recently issued reports on HSIC. StockNews.com downgraded Henry Schein from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Morgan Stanley dropped their price objective on Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research report on Tuesday, February 21st. Credit Suisse Group dropped their price objective on Henry Schein from $99.00 to $97.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 28th. Piper Sandler raised their price objective on Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research report on Monday, February 6th. Finally, Barrington Research dropped their price objective on Henry Schein from $92.00 to $90.00 in a research report on Wednesday, May 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Henry Schein currently has an average rating of “Hold” and an average target price of $85.67.

Henry Schein Price Performance

HSIC opened at $75.08 on Thursday. Henry Schein has a 12-month low of $64.75 and a 12-month high of $89.72. The company has a current ratio of 1.82, a quick ratio of 0.94 and a debt-to-equity ratio of 0.25. The business’s fifty day simple moving average is $80.22 and its 200-day simple moving average is $80.82. The company has a market capitalization of $9.84 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 2.16 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC – Get Rating) last released its earnings results on Tuesday, May 9th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.02). Henry Schein had a return on equity of 15.41% and a net margin of 3.82%. The business had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same quarter in the previous year, the business earned $1.30 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HSIC. Cambridge Investment Research Advisors Inc. grew its holdings in Henry Schein by 2.4% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock valued at $459,000 after purchasing an additional 122 shares during the period. HB Wealth Management LLC grew its holdings in Henry Schein by 0.8% in the first quarter. HB Wealth Management LLC now owns 15,822 shares of the company’s stock valued at $1,290,000 after purchasing an additional 123 shares during the period. ETF Managers Group LLC grew its holdings in Henry Schein by 1.5% in the first quarter. ETF Managers Group LLC now owns 8,278 shares of the company’s stock valued at $675,000 after purchasing an additional 123 shares during the period. Summit Trail Advisors LLC boosted its stake in shares of Henry Schein by 2.1% in the fourth quarter. Summit Trail Advisors LLC now owns 6,323 shares of the company’s stock worth $505,000 after acquiring an additional 132 shares during the last quarter. Finally, Johnson Financial Group Inc. boosted its stake in shares of Henry Schein by 2.0% in the fourth quarter. Johnson Financial Group Inc. now owns 7,515 shares of the company’s stock worth $600,000 after acquiring an additional 145 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Henry Schein news, Director Kurt P. Kuehn sold 1,909 shares of the firm’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the sale, the director now owns 15,675 shares of the company’s stock, valued at $1,214,185.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Kurt P. Kuehn sold 1,909 shares of the firm’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the transaction, the director now directly owns 15,675 shares in the company, valued at $1,214,185.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Michael S. Ettinger sold 14,881 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $75.12, for a total value of $1,117,860.72. Following the completion of the transaction, the chief operating officer now owns 75,710 shares of the company’s stock, valued at $5,687,335.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,942 shares of company stock valued at $3,667,662. 1.14% of the stock is currently owned by corporate insiders.

Henry Schein Company Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.